Home  |  Contact

Cellosaurus Karpas-45 (CVCL_1326)

[Text version]

Cell line name Karpas-45
Synonyms KARPAS-45; Karpas 45; KARPAS 45; KARPAS45; K45; T-45; T45
Accession CVCL_1326
Resource Identification Initiative To cite this cell line use: Karpas-45 (RRID:CVCL_1326)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Doubling time: 50-100 hours (ECACC).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Bone marrow.
Sequence variations Heterozygous for APC p.Val2194Ala (c.6581T>C) (PubMed=22675565; Cosmic-CLP).
Heterozygous for ERBB2 p.Ala586Gly (c.1757C>G) (PubMed=22675565; Cosmic-CLP).
Heterozygous for ETV6 p.His328Tyr (c.982C>T) (PubMed=22675565; Cosmic-CLP).
Heterozygous for FBXW7 p.Arg505Cys (c.1513C>T) (PubMed=22675565; Cosmic-CLP).
Heterozygous for FGFR2 p.Met584Arg (c.1751T>G) (PubMed=22675565; Cosmic-CLP).
Heterozygous for KDR p.Arg962His (c.2885G>A) (PubMed=22675565; Cosmic-CLP).
Heterozygous for KIT p.Asp131Asn (c.391G>A) (PubMed=22675565; Cosmic-CLP).
Heterozygous for MET p.Ala48Thr (c.142G>A) and p.Glu157Gly (c.470A>G) (PubMed=22675565; Cosmic-CLP).
Heterozygous for MSH2 p.Gly221Val (c.662G>T) (PubMed=22675565; Cosmic-CLP).
Heterozygous for NOTCH1 p.Gln2459Ter (c.7375C>T) (PubMed=15472075).
Heterozygous for NOTCH1 p.Asp1852Asn (c.5554G>A) and p.Val2045Ile (c.6133G>A) (PubMed=22675565; Cosmic-CLP).
Heterozygous for PDGFRB p.His277Gln (c.831C>A) (PubMed=22675565; Cosmic-CLP).
Heterozygous for RET p.Asn879Ser (c.2636A>G) (PubMed=22675565; Cosmic-CLP).
Heterozygous for SMARCB1 p.Asn288Lys (c.864C>A) (PubMed=22675565; Cosmic-CLP).
Heterozygous for TP53 p.Arg273Cys (c.817C>T) (PubMed=22675565; Cosmic-CLP).
Heterozygous for WT1 p.Arg394Gln (c.1181G>A) (PubMed=22675565; Cosmic-CLP).
Disease Childhood T acute lymphoblastic leukemia (NCIt: C7953)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 2Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ


Run an STR similarity search on this cell line

Karpas A., Hayhoe F.G.J., Greenberger J.S., Barker C.R., Cawley J.C., Lowenthal R.M., Moloney W.C.
The establishment and cytological, cytochemical and immunological characterisation of human haemic cell lines: evidence for heterogeneity.
Leuk. Res. 1:35-49(1977)

Karpas A.
Viruses and human leukemia in vitro.
(In) Human leukemia. Cytochemical and ultrastructural techniques in diagnosis and research. Developments in Oncology, Vol. 14; Polliack A. (eds.); pp.495-526; Martinus Nijhoff Publishing; Boston (1984)

PubMed=3264071; DOI=10.1073/pnas.85.23.9229
Karpas A., Fleet G.W.J., Dwek R.A., Petursson S., Namgoong S.K., Ramsden N.G., Jacob G.S., Rademacher T.W.
Aminosugar derivatives as potential anti-human immunodeficiency virus agents.
Proc. Natl. Acad. Sci. U.S.A. 85:9229-9233(1988)

PubMed=9933131; DOI=10.1016/S0145-2126(98)00133-7
Burger R., Hansen-Hagge T.E., Drexler H.G., Gramatzki M.
Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines: suggestion for classification by immunophenotype and T-cell receptor studies.
Leuk. Res. 23:19-27(1999)

Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=14671638; DOI=10.1038/sj.leu.2403236
Drexler H.G., Quentmeier H., MacLeod R.A.F.
Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations.
Leukemia 18:227-232(2004)

PubMed=15472075; DOI=10.1126/science.1102160
Weng A.P., Ferrando A.A., Lee W., Morris J.P. IV, Silverman L.B., Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.
Science 306:269-271(2004)

PubMed=15843827; DOI=10.1038/sj.leu.2403749
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia 19:1042-1050(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=22675565; DOI=10.1371/journal.pone.0038463
Kalender Atak Z., De Keersmaecker K., Gianfelici V., Geerdens E., Vandepoel R., Pauwels D., Porcu M., Lahortiga I., Brys V., Dirks W.G., Quentmeier H., Cloos J., Cuppens H., Uyttebroeck A., Vandenberghe P., Cools J., Aerts S.
High accuracy mutation detection in leukemia on a selected panel of cancer genes.
PLoS ONE 7:E38463-E38463(2012)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cell line collections DSMZ; ACC-105 - Discontinued
ECACC; 06072602
NCBI_Iran; C180
Cell line databases/resources CLDB; cl35
Cell_Model_Passport; SIDM01007
Cosmic-CLP; 907272
GDSC; 907272
Ontologies CLO; CLO_0007067
Biological sample resources BioSample; SAMN03473409
Chemistry resources ChEMBL-Cells; CHEMBL3308305
ChEMBL-Targets; CHEMBL2366305
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM1669977
Other Wikidata; Q54899501
Polymorphism and mutation databases Cosmic; 907272
Cosmic; 913413
Cosmic; 1012075
Cosmic; 1151781
Cosmic; 1175130
Cosmic; 1191704
Cosmic; 1281370
Cosmic; 1330505
Cosmic; 1524799
Cosmic; 1664523
Cosmic; 1760525
Cosmic; 2165714
Cosmic; 2391812
Cosmic; 2602917
IARC_TP53; 27173